Kathrin Hillebrand1, Hélène Bricout2, Renate Schulze-Rath3, Tania Schink4, Edeltraut Garbe5. 1. Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstraße 30, 28359 Bremen, Germany. Electronic address: hille@bips.uni-bremen.de. 2. Sanofi Pasteur MSD, Epidemiology Unit, 162, Avenue Jean Jaures, CS50712, 69367 Lyon Cedex 07, France. Electronic address: HBricout@spmsd.com. 3. Sanofi Pasteur MSD GmbH, Paul-Ehrlich-Straße 1, 69181 Leimen, Germany. Electronic address: renate.schulze-rath@bayer.com. 4. Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstraße 30, 28359 Bremen, Germany. Electronic address: schink@bips.uni-bremen.de. 5. Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstraße 30, 28359 Bremen, Germany; Department of Public Health/Health Sciences, University of Bremen, Bremen, Germany. Electronic address: garbe@bips.uni-bremen.de.
Abstract
OBJECTIVES: After introduction of a herpes zoster (HZ) vaccine in Germany in 2013, a potential recommendation by the German Standing Vaccination Committee is still pending. This study estimated data on the disease burden of HZ in Germany to extend the data basis for the decision process. METHODS: A retrospective cohort study on data from 7 million statutory health insurance members from 2005 to 2009 was conducted. HZ cases were identified using ICD-10-codes. IRs of HZ and complications were estimated overall, by age, sex and immune status. The proportion of postherpetic neuralgia (PHN), hospitalizations, the diagnosing physician specialty and systemic antiviral therapy were assessed. RESULTS: Annual standardized IRs ranged between 5.3 and 5.5 per 1000 person-years (PY) between 2006 and 2009 with higher IRs in females. In 2009, 72.4% of HZ patients were without complications, while 15.5% suffered from nervous system involvement. The age-related increase was higher for HZ complications than for uncomplicated HZ. Immunocompromised patients suffered slightly more complications than immunocompetent patients. The PHN proportion increased to 15% in 2009 with a steady age-related increase. About 3% of HZ cases were hospitalized. CONCLUSIONS: Age-related increases of HZ complications and PHN suggest that particularly older patients might benefit from HZ vaccination.
OBJECTIVES: After introduction of a herpes zoster (HZ) vaccine in Germany in 2013, a potential recommendation by the German Standing Vaccination Committee is still pending. This study estimated data on the disease burden of HZ in Germany to extend the data basis for the decision process. METHODS: A retrospective cohort study on data from 7 million statutory health insurance members from 2005 to 2009 was conducted. HZ cases were identified using ICD-10-codes. IRs of HZ and complications were estimated overall, by age, sex and immune status. The proportion of postherpetic neuralgia (PHN), hospitalizations, the diagnosing physician specialty and systemic antiviral therapy were assessed. RESULTS: Annual standardized IRs ranged between 5.3 and 5.5 per 1000 person-years (PY) between 2006 and 2009 with higher IRs in females. In 2009, 72.4% of HZ patients were without complications, while 15.5% suffered from nervous system involvement. The age-related increase was higher for HZ complications than for uncomplicated HZ. Immunocompromised patients suffered slightly more complications than immunocompetent patients. The PHN proportion increased to 15% in 2009 with a steady age-related increase. About 3% of HZ cases were hospitalized. CONCLUSIONS: Age-related increases of HZ complications and PHN suggest that particularly older patients might benefit from HZ vaccination.
Authors: Crystal Stinson; Shaun M Logan; Larry L Bellinger; Mahesh Rao; Paul R Kinchington; Phillip R Kramer Journal: Neuroscience Date: 2019-07-02 Impact factor: 3.590
Authors: Ryan R Thompson; Christina L Kong; Travis C Porco; Eric Kim; Caleb D Ebert; Nisha R Acharya Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 9.079
Authors: Manuel Batram; Julian Witte; Magdalena Schwarz; Johannes Hain; Bernhard Ultsch; Maren Steinmann; Amit Bhavsar; Peter Wutzler; Carl-Peter Criée; Christiane Hermann; Klaus Wahle; Martin Füchtenbusch; Wolfgang Greiner Journal: Dermatol Ther (Heidelb) Date: 2021-05-06
Authors: Max J Hassenstein; Ghazal Aarabi; Peter Ahnert; Heiko Becher; Claus-Werner Franzke; Julia Fricke; Gérard Krause; Stephan Glöckner; Cornelia Gottschick; André Karch; Yvonne Kemmling; Tobias Kerrinnes; Berit Lange; Rafael Mikolajczyk; Alexandra Nieters; Jördis J Ott; Wolfgang Ahrens; Klaus Berger; Claudia Meinke-Franze; Sylvia Gastell; Kathrin Günther; Karin Halina Greiser; Bernd Holleczek; Johannes Horn; Lina Jaeschke; Annika Jagodzinski; Lina Jansen; Carmen Jochem; Karl-Heinz Jöckel; Rudolf Kaaks; Lilian Krist; Oliver Kuß; Susan Langer; Nicole Legath; Michael Leitzmann; Wolfgang Lieb; Markus Loeffler; Nina Mangold; Karin B Michels; Christa Meisinger; Nadia Obi; Tobias Pischon; Tamara Schikowski; Sabine Schipf; Matthias B Schulze; Andreas Stang; Sabina Waniek; Kerstin Wirkner; Stefan N Willich; Stefanie Castell Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2020-04 Impact factor: 1.513